This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

EDMUND L. DUBOIS, M.D.

AMA Arch Intern Med. 1954;94(1):131-141.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Prokoptchouk, in 1940, introduced the use of quinacrine (Atabrine; Mepacrine) for discoid lupus erythematosus,¹ and Popoff² reported similar success. Since the recent report by Page,³ there has been a flurry of confirmatory studies.* One of the patients in Page's series had active systemic lupus, which responded well to 200 mg. of quinacrine daily. In view of this and the fact that there is excellent evidence that systemic lupus erythematosus is a malignant form of the discoid variety, it seemed important to study the use of quinacrine in the generalized form of the disease. Initial studies, in 1952, on three patients with acute systemic lupus erythematosus, using the dose recommended by Page, 200 mg. per day, showed no effect on the disease. The drug was not employed again until further confirmatory reports on its use in the discoid form of the disease appeared. It then seemed that . . . [Full Text PDF of this Article]

Author Affiliations
LOS ANGELES

From the University of Southern California, School of Medicine, Department of Medicine, and the Los Angeles County General Hospital.

Footnotes
This work was supported by the financial aid of Mr. Joseph Gluckstein. Quinacrine (Atabrine) was generously supplied by Dr. J. B. Rice, Winthrop-Stearns, Inc., and cortisone, by Dr. E. Alpert, Merck & Company, Inc.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?